CN104160038B - 一种用于预测对采用egfr抑制剂的治疗的响应性的方法 - Google Patents

一种用于预测对采用egfr抑制剂的治疗的响应性的方法 Download PDF

Info

Publication number
CN104160038B
CN104160038B CN201280067832.4A CN201280067832A CN104160038B CN 104160038 B CN104160038 B CN 104160038B CN 201280067832 A CN201280067832 A CN 201280067832A CN 104160038 B CN104160038 B CN 104160038B
Authority
CN
China
Prior art keywords
patient
hsa
mir
cancer
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280067832.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104160038A (zh
Inventor
T·里奥弗里奥
P·劳伦-皮格
S·因班德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Western Dais Paris, University of
Centre National de la Recherche Scientifique
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
IntegraGen SA
Université Paris Cité
Original Assignee
Centre National de la Recherche Scientifique
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Université Paris Descartes
IntegraGen SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Assistance Publique - Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale, Université Paris Descartes, IntegraGen SA filed Critical Centre National de la Recherche Scientifique
Publication of CN104160038A publication Critical patent/CN104160038A/zh
Application granted granted Critical
Publication of CN104160038B publication Critical patent/CN104160038B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280067832.4A 2011-11-25 2012-11-23 一种用于预测对采用egfr抑制剂的治疗的响应性的方法 Expired - Fee Related CN104160038B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11306568 2011-11-25
EP11306568.4 2011-11-25
EP12306042 2012-08-31
EP12306042.8 2012-08-31
PCT/EP2012/073535 WO2013076282A1 (en) 2011-11-25 2012-11-23 A method for predicting responsiveness to a treatment with an egfr inhibitor

Publications (2)

Publication Number Publication Date
CN104160038A CN104160038A (zh) 2014-11-19
CN104160038B true CN104160038B (zh) 2018-06-12

Family

ID=47297187

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280067832.4A Expired - Fee Related CN104160038B (zh) 2011-11-25 2012-11-23 一种用于预测对采用egfr抑制剂的治疗的响应性的方法

Country Status (10)

Country Link
US (1) US10400284B2 (cg-RX-API-DMAC10.html)
EP (1) EP2783017B1 (cg-RX-API-DMAC10.html)
JP (1) JP6342329B2 (cg-RX-API-DMAC10.html)
KR (1) KR20140104419A (cg-RX-API-DMAC10.html)
CN (1) CN104160038B (cg-RX-API-DMAC10.html)
AU (1) AU2012342397B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014012495A2 (cg-RX-API-DMAC10.html)
CA (1) CA2856594A1 (cg-RX-API-DMAC10.html)
MX (1) MX2014006182A (cg-RX-API-DMAC10.html)
WO (1) WO2013076282A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2931176A1 (en) * 2013-11-26 2015-06-04 Integragen A method for predicting responsiveness to a treatment with an egfr inhibitor
KR101622454B1 (ko) 2014-03-04 2016-05-18 연세대학교 산학협력단 Egfr 티로신 키나아제 억제제에 대한 항암 치료 반응 예측 마커
EP3131552B1 (en) * 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
EP3000895A1 (en) * 2014-09-26 2016-03-30 Integragen A method for predicting responsiveness to a treatment with an EGFR inhibitor
CN107850599B (zh) * 2015-07-23 2021-02-09 新加坡国立大学 Wbp2与her2作为共预后因子对患者分层以进行治疗
EP3450555B1 (en) * 2016-04-28 2020-11-18 Denka Company Limited Method for determining tolerance of cancer cell to epidermal growth factor receptor inhibitor
US12704501B2 (en) 2019-03-29 2026-08-11 Rakuten Medical, Inc. Methods for photoimmunotherapy and related biomarkers
KR102251864B1 (ko) * 2019-10-18 2021-05-14 지니너스 주식회사 miR-320c를 유효성분으로 포함하는 백금계 항암제에 대한 삼중음성유방암 환자의 약물 반응성 예측용 바이오마커 조성물
CN111798918A (zh) * 2020-05-28 2020-10-20 中山大学孙逸仙纪念医院 一种免疫治疗疗效预测的血肿瘤突变算法及其构建方法
CN111863159B (zh) * 2020-06-01 2022-02-25 中山大学孙逸仙纪念医院 一种肿瘤免疫治疗疗效预测的列线图模型的建立方法
WO2023165494A1 (en) * 2022-03-01 2023-09-07 Crown Bioscience (Suzhou) Inc. Methods for determining cetuximab sensitivity in cancer patients

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010121238A2 (en) * 2009-04-17 2010-10-21 Translational Genomics Research Institute (Tgen) Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2439402A1 (en) 2001-03-02 2002-09-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pcr method
RU2010120674A (ru) * 2007-10-22 2011-11-27 Шеринг Корпорейшн (US) Полностью человеческие анти-vegf-антитела и способы их применения
WO2009080437A1 (en) 2007-12-21 2009-07-02 Exiqon A/S Micro-rna based drug resistance analysis method
WO2010015538A2 (en) * 2008-08-05 2010-02-11 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
US9051551B2 (en) * 2009-11-24 2015-06-09 The University Of Western Australia Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors
EP2563936B1 (en) * 2010-04-29 2018-03-14 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010121238A2 (en) * 2009-04-17 2010-10-21 Translational Genomics Research Institute (Tgen) Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MicroRNA Profiling Differentiates Colorectal Cancer According to KRAS Status;Neda Mosakhani et al.;《GENES, CHROMOSOMES & CANCER》;20110915;第51卷;第1-9页 *

Also Published As

Publication number Publication date
JP2014533960A (ja) 2014-12-18
AU2012342397B2 (en) 2018-04-05
US10400284B2 (en) 2019-09-03
US20140370029A1 (en) 2014-12-18
EP2783017B1 (en) 2018-12-26
BR112014012495A2 (pt) 2017-06-06
MX2014006182A (es) 2014-12-08
JP6342329B2 (ja) 2018-06-13
CA2856594A1 (en) 2013-05-30
AU2012342397A1 (en) 2014-06-12
CN104160038A (zh) 2014-11-19
KR20140104419A (ko) 2014-08-28
WO2013076282A1 (en) 2013-05-30
EP2783017A1 (en) 2014-10-01

Similar Documents

Publication Publication Date Title
JP6342329B2 (ja) Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法
US12077803B2 (en) MicroRNAs as biomarkers for endometriosis
Zhao et al. Circulating miRNAs is a potential marker for gefitinib sensitivity and correlation with EGFR mutational status in human lung cancers
EP3198028B1 (en) A method for predicting responsiveness to a treatment with an egfr inhibitor
CN105765081A (zh) 一种用于预测对采用egfr抑制剂的治疗的响应性的方法
WO2015050500A1 (en) Multigene assay for prognosis of renal cancer
US20120095030A1 (en) Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors
US20160304961A1 (en) Method for predicting the response to chemotherapy treatment in patients suffering from colorectal cancer
US20150344961A1 (en) Sera Based miRNAs as Non-Invasive Biomarkers in Melanoma
WO2026050202A1 (en) Biomarkers for use in pancreatic cancer
HK40011172B (en) Micrornas as biomarkers for endometriosis
HK40011172A (en) Micrornas as biomarkers for endometriosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Paris France

Patentee after: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Patentee after: INTEGRAGEN

Patentee after: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Patentee after: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Patentee after: University of Western dais, Paris

Address before: Paris France

Patentee before: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Patentee before: INTEGRAGEN

Patentee before: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Patentee before: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Patentee before: University of Paris

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20221018

Address after: Paris France

Patentee after: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Patentee after: INTEGRAGEN

Patentee after: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Patentee after: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Patentee after: University of Paris

Address before: Paris France

Patentee before: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Patentee before: INTEGRAGEN

Patentee before: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Patentee before: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Patentee before: UNIVERSITE PARIS DESCARTES

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180612

Termination date: 20211123